Latham & Watkins Advises on Seaport Therapeutics’ Upsized US$254.9 Million Initial Public Offering

Seaport Therapeutics, Inc., (Nasdaq: SPTX), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, has announced the pricing of its upsized initial public offering of 14,160,000 shares of its common stock at a price to the public of US$18.00 per share, at the top of the target range. The gross proceeds to Seaport Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$254.9 million. All of the shares are being offered by Seaport Therapeutics. In addition, Seaport Therapeutics has granted the underwriters a 30-day option to buy an additional 2,124,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by New York partners Nathan Ajiashvili, Salvatore Vanchieri, and Sandy Kugbei, with associates Adam Weber and Skye Lee.